Tirzepatide is among the most effective weight loss medications available. Lose up to 25% of your body weight with dual GLP-1/GIP action. Medical supervision at our Sandy and Layton clinics.
Tirzepatide represents the next generation of weight loss medication. Unlike semaglutide which only activates GLP-1 receptors, tirzepatide is a "twincretin"—it activates both GLP-1 and GIP receptors for enhanced metabolic effects.
This dual action makes tirzepatide the most effective FDA-approved medication for weight loss, producing an average of 20-25% body weight loss in clinical trials—about 5% more than semaglutide.
SURMOUNT-1 trial showed 22.5% average weight loss at the highest dose—more than any other FDA-approved medication.
95% of patients achieved clinically significant weight loss of at least 5% of body weight.
63% of patients lost 20% or more of their body weight at the maximum dose.
The average patient lost approximately 52 pounds over the 72-week trial period.
Both are excellent medications, but tirzepatide offers advantages for patients seeking maximum weight loss:
We'll help you choose the best medication for your specific goals and situation.
Free evaluation to assess your health, weight loss goals, and determine if tirzepatide is right for you.
Begin with 2.5mg weekly for 4 weeks to allow your body to adjust and minimize side effects.
Gradually increase dose every 4 weeks (5mg → 7.5mg → 10mg → 12.5mg → 15mg) based on tolerance and response.
Regular check-ins, nutritional guidance, and protocol adjustments to maximize your results.
Tirzepatide activates both GLP-1 and GIP receptors, which can support stronger appetite control, improved insulin sensitivity, and greater overall metabolic response.
Clinical data consistently shows tirzepatide can support substantial body-weight reduction when paired with medical oversight, nutrition support, and consistent follow-up.
We help determine whether tirzepatide is a good fit for your goals, guide your titration schedule, and monitor your progress throughout treatment.
Tirzepatide is a revolutionary dual-action medication that activates both GLP-1 and GIP receptors. It's among the most effective weight loss medications available, helping patients lose up to 25% of their body weight.
Clinical trials show patients lose an average of 20-25% of their body weight with tirzepatide—significantly more than semaglutide. Some patients lose over 50 pounds. Results vary based on starting weight, dose, diet, exercise, and individual response.
Clinical studies show tirzepatide produces greater weight loss than semaglutide (20-25% vs 15-20%). The dual GLP-1/GIP mechanism provides additional metabolic benefits. However, both are highly effective, and the best choice depends on individual factors and tolerability.
Common side effects include nausea, vomiting, diarrhea, constipation, and stomach pain, especially when starting or increasing doses. These typically improve over time. Our gradual titration approach helps minimize side effects.
Tirzepatide is given as a once-weekly subcutaneous injection. Starting dose is 2.5mg, gradually increasing every 4 weeks to the target dose (up to 15mg). We teach you how to self-administer at home with simple injector pens.
Tirzepatide may be appropriate for adults with BMI ≥30 (obesity) or BMI ≥27 with a weight-related condition. It's not recommended for those with personal or family history of medullary thyroid cancer, MEN 2 syndrome, or history of pancreatitis.
Tirzepatide requires a medical evaluation, gradual dose titration, and ongoing monitoring to ensure the treatment is appropriate and well tolerated for your goals.
Schedule your FREE consultation today to learn if tirzepatide is right for you. No obligation, personalized guidance.
Financing available through LiteCredit